Join
Live feed
·
PRReleasevia Quantisnow
PMGC Holdings Inc. logo

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders

ByQuantisnow·Wall Street's wire, on your screen.
ELAB· PMGC Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELAB (PMGC Holdings Inc.) and more on Quantisnow.